Darius Lakdawalla

Jan 22, 2025 | statnews.com | Darius Lakdawalla

Adobe Soon, the Centers for Medicare and Medicaid Services will begin the price negotiation process on a new set of 15 drugs. The new Trump administration should seize the opportunity to change the program to protect the most valuable drug innovation, while also cutting spending on low-value treatments. Peer-reviewed evidence clearly shows that medical innovation suffers when innovators earn less.

Jul 22, 2024 | healthpolicy.usc.edu | Karen Van Nuys |Stephanie Hedt |Geoffrey F. Joyce |Darius Lakdawalla

Patients and consumers bear the costs of an inefficient pharmaceutical distribution system through higher costs at the pharmacy counter and reduced access to critical therapies. As policymakers consider reforms to the drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.

May 26, 2023 | thehill.com | Dana P. Goldman |Darius Lakdawalla

The Inflation Reduction Act of 2022 makes the most dramatic changes to American healthcare since the Affordable Care Act 13 years ago. Of particular note, it empowers Medicare to begin setting ceilings on prescription drug prices.  But the success of the IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.

May 4, 2023 | healthaffairs.org | Jason Shafrin |Darius Lakdawalla |Jalpa A. Doshi |Louis P. Garrison |Anup Malani |Peter J. Neumann | +3 more

Medicare drug price negotiation is almost upon us. The Inflation Reduction Act (IRA) mandates that the Centers for Medicare and Medicaid Services (CMS) implement a maximum fair price (MFP) for drug price negotiation beginning in 2026. How should CMS implement such a program given such a short timeline? We recommend a three-step approach to implementing the MFP that moves toward a drug pricing paradigm based on treatment value.

May 4, 2023 | tinyurl.com | s’ Note |Jason Shafrin |Darius Lakdawalla |Jalpa A. Doshi

Medicare drug price negotiation is almost upon us. The Inflation Reduction Act (IRA) mandates that the Centers for Medicare and Medicaid Services (CMS) implement a maximum fair price (MFP) for drug price negotiation beginning in 2026. How should CMS implement such a program given such a short timeline? We recommend a three-step approach to implementing the MFP that moves toward a drug pricing paradigm based on treatment value.